Aliye BAŞTUĞ, Esragül AKINCI, Hürrem BODUR, Dilek KANYILMAZ, Bircan KAYAASLAN, Berrin SARI, Halide ASLANER, Ayşe BUT, Sevim YAVAŞ, Meltem Arzu YETKİN

Investigating the in vitro synergistic activities of several antibiotic combinationsagainst carbapenem-resistant Acinetobacter baumannii isolates

Background/aim: Acinetobacter baumannii (A. baumannii) is one of the most common healthcare-associated infectious agents worldwide. The aim of this study was to investigate the in vitro synergistic activities of several antibiotic combinations against carbapenem-resistant (CR) A. baumannii isolates. Materials and methods: Eighteen CR A. baumannii strains were isolated from the patients who were hospitalized in the intensive care unit between June 2012 and August 2012. The in vitro effects of single and binary combinations of meropenem (MEM), colistin (CST), tigecycline (TGC), and sulbactam (SUL) on these isolates were determined using the Epsilometer test (E-test) method. Results: All 18 isolates were resistant to MEM and SUL and susceptible to CST. TGC was detected as susceptible in two of the isolates and intermediate susceptibility results were observed in the remaining isolates. With MEM-CST and MEM-TGC combinations, synergism was determined against all isolates. The synergistic and/or additive effect ratios were detected in MEM-SUL, CST-SUL, TGC-SUL, and CST-TGC combinations as 16.7%, 38.9%, 16.7%, and 5.6%, respectively. Conclusion: Among the tested antimicrobial combinations, the in vitro combination of MEM with TGC or CST was most effective against the CR A. baumannii strains.

PDF

___

1. Iacono M, Villa L, Fortini D, Bordoni R, Imperi F, Bonnal RJP, Sicheritz-Ponten T, Bellis G, Visca P, Cassone A, Carattoli A. Whole-genome pyrosequencing of an epidemic multidrugresistant Acinetobacter baumannii strain belonging to the european clone II group. Antimicrob Agents Ch 2008; 52: 2616-2625.
2. Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 2008; 21: 538-582.
3. Akalın H. The antibiotic treatment approach for multidrugresistance and antibiotic stewardship. ANKEM Derg 2007; 21: 186-191 (article in Turkish with an abstract in English).
4. Ürkmez K, Şengöz G. The evaluation of amikacin and meropenem combination according to FIC index criteria with E-test method in resistant Pseudomonas strains (article in Turkish with an abstract in English). Klimik Journal 2005; 18: 45-47.
5. Balke B, Hogardt M, Schmoldt S, Hoy L, Weissbrodt H, Haussler S. Evaluation for the E-test for the assessment of synergy of antibiotic combinations against multiresistant Pseudomonas aeruginosa isolates from cyctic fibrosis patients. Eur J Clin Microbiol 2006; 25: 25-30.
6. Chachanidze V, Curbelo-Irizarry A, Ashcraft D, Pankey G. In vitro synergy of levofloxacin plus piperacillin/tazobactam against Pseudomonas aeruginosa. Interdiscip Perspect Infect Dis 2009; 2009: 984934.
7. Bal Ç. [Antibiyotik kombinasyonlarının in vitro etkinliğinin saptanması.]. FLORA 1999; 4: 219-229 (article in Turkish).
8. The Clinical and Laboratory Standards Institute (CLSI). Zone diameter interpretive standards and equivalent minimal inhibitory concentration (MIC) breakpoints for Acinetobacter species (Table 2B-2). In: Performance Standards for Antimicrobial Susceptibility Testing; 17th Informational Supplement; M100-S17. Wayne, PA, USA: The Clinical and Laboratory Standards Institute (CLSI); 2007. pp. 40-41.
9. Henwood CJ, Gatward T, Warner M, Jamesa D, Stockdalea MW, Spenceb RP, Townerb KJ, Livermorea DM, Woodforda N. Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936). J Antimicrob Chemoth 2002; 49: 479-487.
10. Liang-Yu C, Kuo SC, Liu CY, Luo BS, Huang LJ, Lee YT, Chen CP, Chen TL, Fung CP. Difference in imipenem, meropenem, sulbactam, and colistin nonsusceptibility trends among three phenotypically undifferentiated Acinetobacter baumannii complex in a medical center in Taiwan, 19972007. J Microbiol Immunol 2011; 44: 358-363.
11. Karageorgopoulos DE, Kelesidis T, Kelesidis I, Falagas ME. Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence. J Antimicrob Chemoth 2008; 62: 45-55.
12. Brink AJ, Bizos D, Boffard KD, Feldman C, Grolman DC, Pretorius J, Richards GA, Senekal M, Steyn E, Welkovic N. Guideline: appropriate use of tigecycline. S Afr Med J 2010; 100: 388-394.
13. The European Committee on Antimicrobial Susceptibility Testing (EUCAST). Technical note on tigecycline. Clin Microbiol Infec 2006; 12: 1147-1149.
14. Lewisa RE, Diekema DJ, Messer SA, Pfaller MA, Klepser ME. Comparison of E-test, chequerboard dilution and timekill studies for the detection of synergy or antagonism between antifungal agents tested against Candida species. J Antimicrob Chemoth 2002; 49: 345-351.
15. Mano G, Ugolotti E, Belli ML, Fenu ML, Romano L, Cruciani M. Use of the E-test to assess synergy of antibiotic combinations against isolates of Burkholderia cepacia-complex from patients with cystic fibrosis. Eur J Clin Microbiol 2003; 22: 28-34.
16. Sopirala MM, Mangino JE, Gebreyes WA, Biller B, Bannerman T, Balada-Llasat JM, Pancholi P. Synergy testing by E-test, microdilution checkerboard, and time-kill methods for pandrug-resistant Acinetobacter baumannii. Antimicrob Agents Ch 2010; 54: 4678-4683.
17. Pongpech P, Amornnopparattanakul S, Panapakdee S, Fungwithaya S, Nannha P, Dhiraputra C, Leelarasamee A. Antibacterial activity of carbapenem-based combinations against multidrug-resistant Acinetobacter baumannii. J Med Assoc Thailand 2010; 93: 161-171.
18. Pankey GA, Ashcraft DS. The detection of synergy between meropenem and polymyxin B against meropenem-resistant Acinetobacter baumannii using E-test and time-kill assay. Diagn Micr Infec Dis 2009; 63: 228-232.
19. Tan TY, Lim TP, Lee WHL, Sasikala S, Hsu LY, Kwa ALH. In vitro antibiotic synergy in extensively drug-resistant Acinetobacter baumannii: the effect of testing by time-kill, checkerboard, and E-test methods. Antimicrob Agents Ch 2011; 55: 436-438.
20. Arroyo LA, Mateos I, Gonzalez V, Aznar J. In vitro activities of tigecycline, minocycline, and colistin-tigecycline combination against multi-and pandrug-resistant clinical isolates of Acinetobacter baumannii group. Antimicrob Agents Ch 2009; 53: 1295-1296.
21. Principe L., Arezzo SD, Capone A, Petrosillo N, Visca P. In vitro activity of tigecycline in combination with various antimicrobials against multidrug-resistant Acinetobacter baumannii. Ann Clin Microbiol Antimicrob 2009; 8: 18.
22. Scheetz MH, Qi C, Warren JR, Postelnick MJ, Zembower T, Obias A, Noskin GA. In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenemintermediate or resistant Acinetobacter baumannii. Antimicrob Agents Ch 2007; 51: 1621-1626.
23. Mutlu-Sarıgüzel F, Sümerkan B, Metan G. In-vitro activity of carbapenem/sulbactam combination against Acinetobacter baumannii strains. Erciyes Med J 2010; 32: 15-18 (article in Turkish with an abstract in English).
24. Song JY, Kee SY, Hwang IS, Seo YB, Jeong HW, Kim WJ, Cheong HJ. In vitro activities of carbapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii. J Antimicrob Chemoth 2007; 60: 317-322.
25. Kempf M, Djouhri-Bouktab L, Brunel JM, Raoult D, Rolain JM. Synergistic activity of sulbactam combined with colistin against colistin-resistant Acinetobacter baumannii. Int J Antimicrob Ag 2012; 39: 180-181.
26. Pankuch GA, Lin G, Seifert H, Appelbaum PC. Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii. Antimicrob Agents Ch 2008; 52: 333-336.